Salbutamol Inhalation Aerosol
Indicatios:
Symptomatic treatment of asthma attacks and exacerbations of asthma in adults and children aged 4 years and over. Prevention of exercise-induced bronchospasm or before exposure to a known unavoidable allergen challenge. Symptomatic treatment of broncho-asthma and other conditions associated with reversible airways obstruction.
Salbutamol provides a short-acting bronchodilation with fast onset of action in reversible airways obstruction due to asthma.
Salbutamol Inhalation Aerosol should be used to relieve symptoms when they occur and to prevent them in those circumstances recognised by the patient to precipitate an attack (e.g. before exercise or unavoidable allergen exposure).
Salbutamol is valuable as a rescue medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.
Salbutamol Inhalation Aerosol is indicated in adults, adolescents and children aged 4 to 11 years.
Dosage and administration：
Posology
Adults and Older people:
For the relief of acute bronchospasm and for managing intermittent episodes of asthma, one inhalation (100 micrograms) may be administered as a single starting dose; this may be increased to two inhalations (200 micrograms) if necessary.
Paediatric Population:
Relief of acute bronchospasm
Children aged 4 to 11 years 100 micrograms as required. The dose may be increased to two inhalations if required.
Children aged 12 years and over: Dose as per adult population.
Method of administration
For oral inhalation only.
Contraindications:
Hypersensitivity to salbutamol or to the excipient.
Salbutamol Inhalation Aerosol is contraindicated in treatment of threatened abortion or premature labour.
Precautions:
Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma.
As there may be adverse effects associated with excessive dosing, the dosage and frequency of administration should only be increased on medical advice.
Salbutamol should be administered with caution in patients with thyrotoxicosis, cardiac insufficiency, hypokalaemia, myocardial ischaemia, tachyarrhythmia and hypertrophic obstructive cardiomyopathy.
Rarely inhalation therapy may cause bronchospasm after dosing. In this event, treatment with Salbutamol must be immediately discontinued and, if need be, replaced with another therapy.
Drug interactions:
If additional adrenergic drugs are administered to patients using Salbutamol Easyhaler they should be used with caution to avoid deleterious cardiovascular effects.
Concomitant administration of salbutamol and non-selective ß-blocking drugs such as Propranolol is not recommended.
Patients treated with monoamine oxidase inhibitors or tricyclic antidepressants should be followed clinically in the beginning of salbutamol treatment, because the action of salbutamol on the vascular system may be potentiated.
The simultaneous administration of xanthines, corticosteroids or potassium excreting diuretics may increase hypokalaemia.
Storage:
Store in a dry place at a temperature not exceeding 25°C.